1
|
Somadder PD, Hossain MA, Ahsan A, Sultana T, Soikot SH, Rahman MM, Ibrahim SM, Ahmed K, Bui FM. Drug Repurposing and Systems Biology approaches of Enzastaurin can target potential biomarkers and critical pathways in Colorectal Cancer. Comput Biol Med 2023; 155:106630. [PMID: 36774894 DOI: 10.1016/j.compbiomed.2023.106630] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2022] [Revised: 01/28/2023] [Accepted: 02/04/2023] [Indexed: 02/10/2023]
Abstract
Colorectal cancer (CRC) is a severe health concern that results from a cocktail of genetic, epigenetic, and environmental abnormalities. Because it is the second most lethal malignancy in the world and the third-most common malignant tumor, but the treatment is unavailable. The goal of the current study was to use bioinformatics and systems biology techniques to determine the pharmacological mechanism underlying putative important genes and linked pathways in early-onset CRC. Computer-aided methods were used to uncover similar biological targets and signaling pathways associated with CRC, along with bioinformatics and network pharmacology techniques to assess the effects of enzastaurin on CRC. The KEGG and gene ontology (GO) pathway analysis revealed several significant pathways including in positive regulation of protein phosphorylation, negative regulation of the apoptotic process, nucleus, nucleoplasm, protein tyrosine kinase activity, PI3K-Akt signaling pathway, pathways in cancer, focal adhesion, HIF-1 signaling pathway, and Rap1 signaling pathway. Later, the hub protein module identified from the protein-protein interactions (PPIs) network, molecular docking and molecular dynamics simulation represented that enzastaurin showed strong binding interaction with two hub proteins including CASP3 (-8.6 kcal/mol), and MCL1 (-8.6 kcal/mol), which were strongly implicated in CRC management than other the five hub proteins. Moreover, the pharmacokinetic features of enzastaurin revealed that it is an effective therapeutic agent with minimal adverse effects. Enzastaurin may inhibit the potential biological targets that are thought to be responsible for the advancement of CRC and this study suggests a potential novel therapeutic target for CRC.
Collapse
Affiliation(s)
- Pratul Dipta Somadder
- Department of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Tangail, 1092, Bangladesh.
| | - Md Arju Hossain
- Department of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Tangail, 1092, Bangladesh.
| | - Asif Ahsan
- Department of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Tangail, 1092, Bangladesh.
| | - Tayeba Sultana
- Department of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Tangail, 1092, Bangladesh.
| | - Sadat Hossain Soikot
- Department of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Tangail, 1092, Bangladesh.
| | - Md Masuder Rahman
- Department of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Tangail, 1092, Bangladesh.
| | - Sobhy M Ibrahim
- Department of Biochemistry, College of Science, King Saud University, P.O. Box 2455, Riyadh, 11451, Saudi Arabia.
| | - Kawsar Ahmed
- Department of Electrical and Computer Engineering, University of Saskatchewan, 57 Campus Drive, Saskatoon, SK, S7N 5A9, Canada; Group of Biophotomatiχ, Department of Information and Communication Technology, Mawlana Bhashani Science and Technology University, Santosh, Tangail, 1902, Bangladesh.
| | - Francis M Bui
- Department of Electrical and Computer Engineering, University of Saskatchewan, 57 Campus Drive, Saskatoon, SK, S7N 5A9, Canada.
| |
Collapse
|
2
|
Lin CC, Suen KM, Jeffrey PA, Wieteska L, Lidster JA, Bao P, Curd AP, Stainthorp A, Seiler C, Koss H, Miska E, Ahmed Z, Evans SD, Molina-París C, Ladbury JE. Receptor tyrosine kinases regulate signal transduction through a liquid-liquid phase separated state. Mol Cell 2022; 82:1089-1106.e12. [PMID: 35231400 PMCID: PMC8937303 DOI: 10.1016/j.molcel.2022.02.005] [Citation(s) in RCA: 33] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2019] [Revised: 11/02/2021] [Accepted: 02/01/2022] [Indexed: 11/20/2022]
Abstract
The recruitment of signaling proteins into activated receptor tyrosine kinases (RTKs) to produce rapid, high-fidelity downstream response is exposed to the ambiguity of random diffusion to the target site. Liquid-liquid phase separation (LLPS) overcomes this by providing elevated, localized concentrations of the required proteins while impeding competitor ligands. Here, we show a subset of phosphorylation-dependent RTK-mediated LLPS states. We then investigate the formation of phase-separated droplets comprising a ternary complex including the RTK, (FGFR2); the phosphatase, SHP2; and the phospholipase, PLCγ1, which assembles in response to receptor phosphorylation. SHP2 and activated PLCγ1 interact through their tandem SH2 domains via a previously undescribed interface. The complex of FGFR2 and SHP2 combines kinase and phosphatase activities to control the phosphorylation state of the assembly while providing a scaffold for active PLCγ1 to facilitate access to its plasma membrane substrate. Thus, LLPS modulates RTK signaling, with potential consequences for therapeutic intervention.
Collapse
Affiliation(s)
- Chi-Chuan Lin
- School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, UK.
| | - Kin Man Suen
- School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, UK; Wellcome Trust Cancer Research UK Gurdon Institute, University of Cambridge, Tennis Court Road, Cambridge CB2 1QN, UK
| | | | - Lukasz Wieteska
- School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, UK
| | - Jessica A Lidster
- School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, UK
| | - Peng Bao
- School of Physics and Astronomy, University of Leeds, Leeds LS2 9JT, UK
| | - Alistair P Curd
- School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, UK
| | - Amy Stainthorp
- School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, UK
| | - Caroline Seiler
- School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, UK
| | - Hans Koss
- Institute of Structural and Molecular Biology, Division of Biosciences, University College London, Gower Street, London WC1E 6BT, UK; Francis Crick Institute, London NW1 1AT, UK
| | - Eric Miska
- Wellcome Trust Cancer Research UK Gurdon Institute, University of Cambridge, Tennis Court Road, Cambridge CB2 1QN, UK
| | - Zamal Ahmed
- Department of Molecular and Cellular Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
| | - Stephen D Evans
- School of Physics and Astronomy, University of Leeds, Leeds LS2 9JT, UK
| | | | - John E Ladbury
- School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, UK.
| |
Collapse
|
3
|
Bijian K, Wernic D, Nivedha AK, Su J, Lim FPL, Miron CE, Amzil H, Moitessier N, Alaoui-Jamali MA. Novel Aurora A and Protein Kinase C (α, β1, β2, and θ) Multitarget Inhibitors: Impact of Selenium Atoms on the Potency and Selectivity. J Med Chem 2022; 65:3134-3150. [PMID: 35167283 DOI: 10.1021/acs.jmedchem.1c01031] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Aurora kinases and protein kinase C (PKC) have been shown to be involved in different aspects of cancer progression. To date, no dual Aurora/PKC inhibitor with clinical efficacy and low toxicity is available. Here, we report the identification of compound 2e as a potent small molecule capable of selectively inhibiting Aurora A kinase and PKC isoforms α, β1, β2 and θ. Compound 2e demonstrated significant inhibition of the colony forming ability of metastatic breast cancer cells in vitro and metastasis development in vivo. In vitro kinase screening and molecular modeling studies revealed the critical role of the selenium-containing side chains within 2e, where selenium atoms were shown to significantly improve its selectivity and potency by forming additional interactions and modulating the protein dynamics. In comparison to other H-bonding heteroatoms such as sulfur, our studies suggested that these selenium atoms also confer more favorable PK properties.
Collapse
Affiliation(s)
- Krikor Bijian
- Segal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Departments of Medicine and Oncology, McGill University, Montreal, Quebec H3A 0B8, Canada
| | - Dominik Wernic
- Segal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Departments of Medicine and Oncology, McGill University, Montreal, Quebec H3A 0B8, Canada
| | - Anita K Nivedha
- Department of Chemistry, McGill University, Montréal, Québec H3A 0B8, Canada.,Molecular Forecaster, 7171 rue Frederick Banting, Saint Laurent, Quebec H4S 1Z9, Canada
| | - Jie Su
- Segal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Departments of Medicine and Oncology, McGill University, Montreal, Quebec H3A 0B8, Canada
| | | | - Caitlin E Miron
- Department of Chemistry, McGill University, Montréal, Québec H3A 0B8, Canada
| | - Hind Amzil
- Segal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Departments of Medicine and Oncology, McGill University, Montreal, Quebec H3A 0B8, Canada
| | - Nicolas Moitessier
- Department of Chemistry, McGill University, Montréal, Québec H3A 0B8, Canada
| | - Moulay A Alaoui-Jamali
- Segal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Departments of Medicine and Oncology, McGill University, Montreal, Quebec H3A 0B8, Canada
| |
Collapse
|
4
|
Bhaskar BV, Rammohan A, Babu TM, Zheng GY, Chen W, Rajendra W, Zyryanov GV, Gu W. Molecular insight into isoform specific inhibition of PI3K-α and PKC-η with dietary agents through an ensemble pharmacophore and docking studies. Sci Rep 2021; 11:12150. [PMID: 34108504 PMCID: PMC8190100 DOI: 10.1038/s41598-021-90287-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2020] [Accepted: 04/29/2021] [Indexed: 02/05/2023] Open
Abstract
Dietary compounds play an important role in the prevention and treatment of many cancers, although their specific molecular mechanism is not yet known. In the present study, thirty dietary agents were analyzed on nine drug targets through in silico studies. However, nine dietary scaffolds, such as silibinin, flavopiridol, oleandrin, ursolic acid, α-boswellic acid, β-boswellic acid, triterpenoid, guggulsterone, and oleanolic acid potentially bound to the cavity of PI3K-α, PKC-η, H-Ras, and Ras with the highest binding energy. Particularly, the compounds silibinin and flavopiridol have been shown to have broad spectrum anticancer activity. Interestingly, flavopiridol was embedded in the pockets of PI3K-α and PKC-η as bound crystal inhibitors in two different conformations and showed significant interactions with ATP binding pocket residues. However, complex-based pharmacophore modeling achieved two vital pharmacophoric features namely, two H-bond acceptors for PI3K-α, while three are hydrophobic, one cat-donor and one H-bond donor and acceptor for PKC-η, respectively. The database screening with the ChemBridge core library explored potential hits on a valid pharmacophore query. Therefore, to optimize perspective lead compounds from the hits, which were subjected to various constraints such as docking, MM/GBVI, Lipinski rule of five, ADMET and toxicity properties. Henceforth, the top ligands were sorted out and examined for vital interactions with key residues, arguably the top three promising lead compounds for PI3K-α, while seven for PKC-η, exhibiting binding energy from - 11.5 to - 8.5 kcal mol-1. Therefore, these scaffolds could be helpful in the development of novel class of effective anticancer agents.
Collapse
Affiliation(s)
- Baki Vijaya Bhaskar
- Department of Pathophysiology, The Key Immunopathology Laboratory of Guangdong Province, Shantou University Medical College, Xinling Road, Shantou, 515041, Guangdong, China.
| | - Aluru Rammohan
- Department of Organic and Biomolecular Chemistry, Ural Federal University, Ekaterinburg, 620002, Russia
| | | | - Gui Yu Zheng
- Department of Pathophysiology, The Key Immunopathology Laboratory of Guangdong Province, Shantou University Medical College, Xinling Road, Shantou, 515041, Guangdong, China
| | - Weibin Chen
- Department of Pathophysiology, The Key Immunopathology Laboratory of Guangdong Province, Shantou University Medical College, Xinling Road, Shantou, 515041, Guangdong, China
| | - Wudayagiri Rajendra
- Department of Zoology, Sri Venkateswara University, Tirupati, Andhra Pradesh, 517502, India
| | - Grigory V Zyryanov
- Department of Organic and Biomolecular Chemistry, Ural Federal University, Ekaterinburg, 620002, Russia
| | - Wei Gu
- Department of Pathophysiology, The Key Immunopathology Laboratory of Guangdong Province, Shantou University Medical College, Xinling Road, Shantou, 515041, Guangdong, China.
| |
Collapse
|
5
|
Tyagi K, Roy A. Evaluating the current status of protein kinase C (PKC)-protein kinase D (PKD) signalling axis as a novel therapeutic target in ovarian cancer. Biochim Biophys Acta Rev Cancer 2020; 1875:188496. [PMID: 33383102 DOI: 10.1016/j.bbcan.2020.188496] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2020] [Revised: 12/19/2020] [Accepted: 12/19/2020] [Indexed: 12/14/2022]
Abstract
Ovarian cancer, especially high grade serous ovarian cancer is one of the most lethal gynaecological malignancies with high relapse rate and patient death. Notwithstanding development of several targeted treatment and immunotherapeutic approaches, researchers fail to turn ovarian cancer into a manageable disease. Protein kinase C (PKC) and protein kinase D (PKD) are families of evolutionarily conserved serine/threonine kinases that can be activated by a plethora of extracellular stimuli such as hormones, growth factors and G-protein coupled receptor agonists. Recent literature suggests that a signalling cascade initiated by these two protein kinases regulates a battery of cellular and physiological processes involved in tumorigenesis including cell proliferation, migration, invasion and angiogenesis. In an urgent need to discover novel therapeutic interventions against a deadly pathology like ovarian cancer, we have discussed the status quo of PKC/PKD signalling axis in context of this disease. Additionally, apart from discussing the structural properties and activation mechanisms of PKC/PKD, we have provided a comprehensive review of the recent reports on tumor promoting functions of PKC isoforms and discussed the potential of PKC/PKD signalling axis as a novel target in this lethal pathology. Furthermore, in this review, we have discussed the significance of several recent clinical trials and development of small molecule inhibitors that target PKC/PKD signalling axis in ovarian cancer.
Collapse
Affiliation(s)
- Komal Tyagi
- Amity Institute of Molecular Medicine and Stem Cell Research, Amity University, Sector-125, Noida, Uttar Pradesh 201303, India
| | - Adhiraj Roy
- Amity Institute of Molecular Medicine and Stem Cell Research, Amity University, Sector-125, Noida, Uttar Pradesh 201303, India.
| |
Collapse
|
6
|
Tang YH, Liang TT, Fan TT, Keen LJ, Zhang XD, Xu L, Zhao Q, Zeng R, Han BN. Neo-debromoaplysiatoxin C, with new structural rearrangement, derived from debromoaplysiatoxin. Nat Prod Res 2019; 34:2151-2156. [PMID: 30835553 DOI: 10.1080/14786419.2019.1577840] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Neo-debromoaplysiatoxin C (1), a new member of the aplysiatoxin family, was isolated from the marine cyanobacterium Lyngbya sp. The structure of 1 was elucidated based on spectroscopic data, and its stereochemistry was determined from NOESY spectrum and biosynthetic considerations. This new compound presents an intriguing 10-membered lactone ring skeleton derived from debromoaplysiatoxin by structural rearrangement, which is the first example in the aplysiatoxin family. Its biological properties were evaluated for cytotoxicity, PKCδ activation and inhibitory effects on potassium channel.
Collapse
Affiliation(s)
- Yang-Hua Tang
- Department of Pharmacy, Graduate School, Hunan University of Chinese Medicine, Changsha, People's Republic of China.,Department of Development Technology of Marine Resources, College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, People's Republic of China
| | - Ting-Ting Liang
- Department of Development Technology of Marine Resources, College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, People's Republic of China.,School of Chemical and Environmental Engineering, Shanghai Institute of Technology, Shanghai, People's Republic of China
| | - Ting-Ting Fan
- Department of Development Technology of Marine Resources, College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, People's Republic of China
| | - Lawrence Jordan Keen
- Department of Development Technology of Marine Resources, College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, People's Republic of China
| | - Xiao-Dan Zhang
- Department of Development Technology of Marine Resources, College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, People's Republic of China
| | - Lin Xu
- Department of Development Technology of Marine Resources, College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, People's Republic of China
| | - Qi Zhao
- Faculty of Health Sciences, University of Macau, Macau, China
| | - Rong Zeng
- Department of Pharmacy, Graduate School, Hunan University of Chinese Medicine, Changsha, People's Republic of China
| | - Bing-Nan Han
- Department of Development Technology of Marine Resources, College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, People's Republic of China
| |
Collapse
|
7
|
Markovsky E, de Stanchina E, Itzkowitz A, Haimovitz-Friedman A, Rotenberg SA. Phosphorylation state of Ser 165 in α-tubulin is a toggle switch that controls proliferating human breast tumors. Cell Signal 2018; 52:74-82. [PMID: 30176291 PMCID: PMC6765385 DOI: 10.1016/j.cellsig.2018.08.021] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2018] [Revised: 08/29/2018] [Accepted: 08/31/2018] [Indexed: 11/18/2022]
Abstract
Engineered overexpression of protein kinase Cα (PKCα) is known to phosphorylate Ser165 in α-tubulin resulting in stimulated microtubule dynamics and cell motility, and activation of an epithelial-mesenchymal transition (EMT) in non-transformed human breast cells. Here it is shown that endogenous phosphorylation of native α-tubulin in two metastatic breast cell lines, MDA-MB-231-LM2-4175 and MDA-MB-468 is detected at PKC phosphorylation sites. α-Tubulin mutants that simulated phosphorylated (S165D) or non-phosphorylated (S165 N) states were stably expressed in MDA-MB-231-LM2-4175 cells. The S165D-α-tubulin mutant engendered expression of the EMT biomarker N-cadherin, whereas S165 N-α-tubulin suppressed N-cadherin and induced E-cadherin expression, revealing a 'cadherin switch'. S165 N-α-tubulin engendered more rapid passage through the cell cycle, induced shorter spindle fibers and exhibited more rapid proliferation. In nude mice injected with MDA-MB-231-LM2-4175 cells, cells expressing S165 N-α-tubulin (but not the S165D mutant) produced hyper-proliferative lung tumors with increased tumor incidence and higher Ki67 expression. These results implicate the phosphorylation state of Ser165 in α-tubulin as a PKC-regulated molecular switch that causes breast cells to exhibit either EMT characteristics or hyper-proliferation. Evaluation of genomic databases of human tumors strengthens the clinical significance of these findings.
Collapse
Affiliation(s)
| | - Elisa de Stanchina
- Antitumor Assessment Core Facility of Memorial Sloan-Kettering Cancer Institute, USA
| | | | | | - Susan A Rotenberg
- Department of Chemistry & Biochemistry, Queens College, USA; Graduate Center of The City University of New York, USA.
| |
Collapse
|
8
|
Kharkar PS. Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015). Expert Opin Ther Pat 2017; 27:753-761. [PMID: 28460551 DOI: 10.1080/13543776.2017.1325465] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Prashant S. Kharkar
- Department of Pharmaceutical Chemistry, SPP School of Pharmacy and Technology Management, SVKM’s NMIMS, Mumbai, India
| |
Collapse
|
9
|
Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst 2016; 108:djw182. [PMID: 27576731 DOI: 10.1093/jnci/djw182] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2015] [Accepted: 06/17/2016] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Therapies cotargeting insulin-like growth factor receptor 1 (IGF-1R) and mammalian target of rapamycin (mTOR) have demonstrated remarkable, albeit short-lived, clinical responses in a subset of Ewing sarcoma (ES) patients. However, the mechanisms of resistance and applicable strategies for overcoming drug resistance to the IGF-1R/mTOR blockade are still undefined. METHODS To elucidate predominant mechanism(s) of acquired drug resistance while identifying synergistic drug combinations that improve clinical efficacy, we generated more than 18 ES cell lines resistant to IGF-1R- or mTOR-targeted therapy. Two small-molecule inhibitors of IGF-1R were chosen, NVP-ADW-742 (IGF-1R-selective) and OSI-906 (a dual IGF-1R/insulin receptor alpha [IR-α] inhibitor). Reverse-phase protein lysate arrays (RPPAs) revealed proteomic changes linked to IGF-1R/mTOR resistance, and selected proteins were validated in cell-based assays, xenografts, and within human clinical samples. All statistical tests were two-sided. RESULTS Novel mechanisms of resistance (MOR) emerged after dalotuzumab-, NVP-ADW-742-, and OSI-906-based targeting of IGF-1R. MOR to dalotuzumab included upregulation of IRS1, PI3K, and STAT3, as well as p38 MAPK, which was also induced by OSI-906. pEIF4E(Ser209), a key regulator of Cap-dependent translation, was induced in ridaforolimus-resistant ES cell lines. Unique drug combinations targeting IGF-1R and PI3K-alpha or Mnk and mTOR were synergistic in vivo and vitro (P < .001) as assessed respectively by Mantel-Cox and isobologram testing. CONCLUSIONS We discovered new druggable targets expressed by chemoresistant ES cells, xenografts, and relapsed human tumors. Joint suppression of these newfound targets, in concert with IGF-1R or mTOR blockade, should improve clinical outcomes.
Collapse
Affiliation(s)
- Salah-Eddine Lamhamedi-Cherradi
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| | - Brian A Menegaz
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| | - Vandhana Ramamoorthy
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| | - Deeksha Vishwamitra
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| | - Ying Wang
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| | - Rebecca L Maywald
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| | - Adriana S Buford
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| | - Izabela Fokt
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| | - Stanislaw Skora
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| | - Jing Wang
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| | - Aung Naing
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| | - Alexander J Lazar
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| | - Eric M Rohren
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| | - Najat C Daw
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| | - Vivek Subbiah
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| | - Robert S Benjamin
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| | - Ravin Ratan
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| | - Waldemar Priebe
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| | - Antonios G Mikos
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| | - Hesham M Amin
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| | - Joseph A Ludwig
- Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM)
| |
Collapse
|
10
|
Kawahara R, Granato DC, Yokoo S, Domingues RR, Trindade DM, Paes Leme AF. Mass spectrometry-based proteomics revealed Glypican-1 as a novel ADAM17 substrate. J Proteomics 2016; 151:53-65. [PMID: 27576135 DOI: 10.1016/j.jprot.2016.08.017] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2016] [Revised: 08/02/2016] [Accepted: 08/25/2016] [Indexed: 12/16/2022]
Abstract
ADAM17 (a disintegrin and metalloproteinase 17) is a plasma membrane metalloprotease involved in proteolytic release of the extracellular domain of many cell surface molecules, a process known as ectodomain shedding. Through this process, ADAM17 is implicated in several aspects of tumor growth and metastasis in a broad range of tumors, including head and neck squamous cell carcinomas (HNSCC). In this study, mass spectrometry-based proteomics approaches revealed glypican-1 (GPC1) as a new substrate for ADAM17, and its shedding was confirmed to be metalloprotease-dependent, induced by a pleiotropic agent (PMA) and physiologic ligand (EGF), and inhibited by marimastat. In addition, immunoblotting analysis of GPC1 in the extracellular media from control and ADAM17shRNA pointed to a direct involvement of ADAM17 in the cleavage of GPC1. Moreover, mass spectrometry-based interactome analysis of GPC1 revealed biological functions and pathways related mainly to cellular movement, adhesion and proliferation, which were events also modulated by up regulation of full length and cleavage GPC1. Altogether, we showed that GPC1 is a novel ADAM17 substrate, thus the function of GPC1 may be modulated by proteolysis signaling. BIOLOGICAL SIGNIFICANCE Inhibition of metalloproteases as a therapeutic approach has failed because there is limited knowledge of the degradome of individual proteases as well as the cellular function of cleaved substrates. Using different proteomic techniques, this study uncovered novel substrates that can be modulated by ADAM17 in oral squamous cell carcinoma cell line. Glypican-1 was validated as a novel substrate for ADAM17, with important function in adhesion, proliferation and migration of carcinoma cells. Therefore, this study opens new avenues regarding the proteolysis-mediated function of GPC1 by ADAM17.
Collapse
Affiliation(s)
- Rebeca Kawahara
- Laboratório Nacional de Biociências, LNBio, CNPEM, Campinas, Brazil
| | | | - Sami Yokoo
- Laboratório Nacional de Biociências, LNBio, CNPEM, Campinas, Brazil
| | | | | | | |
Collapse
|
11
|
PKCε inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P. Cancer Lett 2016; 376:148-54. [PMID: 27037060 DOI: 10.1016/j.canlet.2016.03.041] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2015] [Revised: 03/12/2016] [Accepted: 03/22/2016] [Indexed: 12/11/2022]
Abstract
Protein kinase C epsilon (PKCε), a member of the novel PKC family, is known to be a transforming oncogene and tumor biomarker for many human solid cancers including renal cell carcinoma (RCC). We isolated side population (SP) cells from the RCC 769P cell line, and proved that those cells possess cancer stem cell (CSC) characteristics. In this study, to identify the function of PKCε in cancer stemness of 769P SP cells, we reduced the expression of PKCε in those cells, following the results demonstrated that PKCε depletion had a negative correlation with the existence of SP cells in 769P cell line. Down-regulation of PKCε also suppresses the CSC potential of sorted 769P SP cells in several ways: proliferation potential, resistance to chemotherapeutics and in vivo tumor formation ability. Our study also reveals that PKCε is associated with ABCB1 and this association probably contributed to the SP cells isolation from 769P cell line. Furthermore, the expression of ABCB1 is directly regulated by PKCε. Additionally, after the depletion of PKCε, the phosphorylation of pAkt, pStat3 and pERK was apparently suppressed in 769P SP cells, whereas PKCε overexpression could promote the phosphorylation of AKT, STAT3 and ERK in 769P Non-SP cells. Overall, PKCε down-regulation suppresses sorting and the cancer stem-like phenotype of RCC 769P SP cells through the regulation of ABCB1 transporter and the PI3K/Akt, Stat3 and MAPK/ERK pathways that are dependent on the phosphorylation effects. Thus, PKCε may work as an important mediator in cancer stem cell pathogenesis of renal cell cancer.
Collapse
|
12
|
Pany S, Majhi A, Das J. Selective Modulation of Protein Kinase C α over Protein Kinase C ε by Curcumin and Its Derivatives in CHO-K1 Cells. Biochemistry 2016; 55:2135-43. [PMID: 26983836 DOI: 10.1021/acs.biochem.6b00057] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Members of the protein kinase C (PKC) family of serine/threonine kinases regulate various cellular functions, including cell growth, differentiation, metabolism, and apoptosis. Modulation of isoform-selective activity of PKC by curcumin (1), the active constituent of Curcuma L., is poorly understood, and the literature data are inconsistent and obscure. The effect of curcumin (1) and its analogues, 4-[(2Z,6E)-3-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-5-oxohepta-2,6-dien-1-yl]-2-methoxyphenyl oleate (2), (9Z,12Z)-4-[(2Z,6E)-3-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-5-oxohepta-2,6-dien-1-yl]-2-methoxyphenyl octadeca-9,12-dienoate (3), (9Z,12Z,15Z)-4-[(2Z,6E)-3-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-5-oxohepta-2,6-dien-1-yl]-2-methoxyphenyl octadeca-9,12,15-trienoate (4), and (1E,6E)-1-[4-(hexadecyloxy)-3-methoxyphenyl]-7-(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione (5), and didemethylcurcumin (6) on the membrane translocation of PKCα, a conventional PKC, and PKCε, a novel PKC, has been studied in CHO-K1 cells, in which these PKC isoforms are endogenously expressed. Translocation of PKC from the cytosol to the membrane was measured using immunoblotting and confocal microscopy. 1 and 6 inhibited the TPA-induced membrane translocation of PKCα but not of PKCε. Modification of the hydroxyl group of curcumin with a long aliphatic chain containing unsaturated double bonds in 2-4 completely abolished this inhibition property. Instead, 2-4 showed significant translocation of PKCα but not of PKCε to the membrane. No membrane translocation was observed with 1, 6, or the analogue 5 having a saturated long chain for either PKCα or PKCε. 1 and 6 inhibited TPA-induced activation of ERK1/2, and 2-4 activated it. ERK1/2 is the downstream readout of PKC. These results show that the hydroxyl group of curcumin is important for PKC activity and the curcumin template can be useful in developing isoform specific PKC modulators for regulating a particular disease state.
Collapse
Affiliation(s)
- Satyabrata Pany
- Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston , Houston, Texas 77204, United States
| | - Anjoy Majhi
- Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston , Houston, Texas 77204, United States
| | - Joydip Das
- Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston , Houston, Texas 77204, United States
| |
Collapse
|
13
|
Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Aiyer RA, Maywald RL, Buford AS, Doolittle DK, Culotta KS, O'Dorisio JE, Ludwig JA. An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma. Mol Cancer Ther 2015; 14:1591-604. [PMID: 25964201 DOI: 10.1158/1535-7163.mct-14-0334] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2014] [Accepted: 04/28/2015] [Indexed: 11/16/2022]
Abstract
Ewing sarcoma is a transcription factor-mediated pediatric bone tumor caused by a chromosomal translocation of the EWSR1 gene and one of several genes in the ETS family of transcription factors, typically FLI1 or ERG. Full activity of the resulting oncogenic fusion protein occurs only after binding RNA helicase A (RHA), and novel biologically targeted small molecules designed to interfere with that interaction have shown early promise in the preclinical setting. Herein, we demonstrate marked preclinical antineoplastic activity of an orally bioavailable formulation of YK-4-279 and identify mechanisms of acquired chemotherapy resistance that may be exploited to induce collateral sensitivity. Daily enteral administration of YK-4-279 led to significant delay in Ewing sarcoma tumor growth within a murine model. In advance of anticipated early-phase human clinical trials, we investigated both de novo and acquired mechanism(s) by which Ewing sarcoma cells evade YK-4-279-mediated cell death. Drug-resistant clones, formed by chronic in vitro exposure to steadily increased levels of YK-4-279, overexpressed c-Kit, cyclin D1, pStat3(Y705), and PKC isoforms. Interestingly, cross-resistance to imatinib and enzastaurin (selective inhibitors of c-Kit and PKC-β, respectively), was observed and the use of YK-4-279 with enzastaurin in vitro led to marked drug synergy, suggesting a potential role for combination therapies in the future. By advancing an oral formulation of YK-4-279 and identifying prominent mechanisms of resistance, this preclinical research takes us one step closer to a shared goal of curing adolescents and young adults afflicted by Ewing sarcoma.
Collapse
MESH Headings
- Administration, Oral
- Animals
- Area Under Curve
- Blotting, Western
- Cell Line, Tumor
- Cell Proliferation/drug effects
- Cell Proliferation/genetics
- Cell Survival/drug effects
- Cell Survival/genetics
- Drug Resistance, Neoplasm
- Gene Expression Profiling/methods
- Humans
- Indoles/administration & dosage
- Indoles/pharmacokinetics
- Indoles/pharmacology
- Interleukin Receptor Common gamma Subunit/deficiency
- Interleukin Receptor Common gamma Subunit/genetics
- Male
- Mice, Inbred NOD
- Mice, Knockout
- Mice, SCID
- Proteomics/methods
- Reverse Transcriptase Polymerase Chain Reaction
- Sarcoma, Ewing/drug therapy
- Sarcoma, Ewing/genetics
- Sarcoma, Ewing/metabolism
- Survival Analysis
- Tissue Distribution
- Treatment Outcome
- Tumor Burden/drug effects
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
| | - Brian A Menegaz
- Department of Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, Texas
| | - Vandhana Ramamoorthy
- Department of Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, Texas
| | | | - Rebecca L Maywald
- Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas
| | - Adrianna S Buford
- Department of Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, Texas
| | - Dannette K Doolittle
- Laboratory of Experimental Therapeutics, MD Anderson Cancer Center, Houston, Texas
| | - Kirk S Culotta
- Laboratory of Experimental Therapeutics, MD Anderson Cancer Center, Houston, Texas
| | | | - Joseph A Ludwig
- Department of Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, Texas.
| |
Collapse
|
14
|
Chen CH, Statt S, Chiu CL, Thai P, Arif M, Adler KB, Wu R. Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications. Am J Respir Crit Care Med 2015; 190:1127-38. [PMID: 25318062 DOI: 10.1164/rccm.201408-1505oc] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
RATIONALE Phosphorylation of myristoylated alanine-rich C kinase substrate (phospho-MARCKS) at the phosphorylation site domain (PSD) is crucial for mucus granule secretion and cell motility, but little is known concerning its function in lung cancer. OBJECTIVES We aimed to determine if MARCKS PSD activity can serve as a therapeutic target and to elucidate the molecular basis of this potential. METHODS The clinical relevance of phospho-MARCKS was first confirmed. Next, we used genetic approaches to verify the functionality and molecular mechanism of phospho-MARCKS. Finally, cancer cells were pharmacologically inhibited for MARCKS activity and subjected to functional bioassays. MEASUREMENTS AND MAIN RESULTS We demonstrated that higher phospho-MARCKS levels were correlated with shorter overall survival of lung cancer patients. Using shRNA silencing and ectopic expression of wild-type and PSD-mutated (S159/163A) MARCKS, we showed that elevated phospho-MARCKS promoted cancer growth and erlotinib resistance. Further studies demonstrated an interaction of phosphoinositide 3-kinase with MARCKS, but not with phospho-MARCKS. Interestingly, phospho-MARCKS acted in parallel with increased phosphatidylinositol (3,4,5)-triphosphate pools and AKT activation in cells. Through treatment with a 25-mer peptide targeting the MARCKS PSD motif (MPS peptide), we were able to suppress tumor growth and metastasis in vivo, and reduced levels of phospho-MARCKS, phosphatidylinositol (3,4,5)-triphosphate, and AKT activity. This peptide also enhanced the sensitivity of lung cancer cells to erlotinib treatment, especially those with sustained activation of phosphoinositide 3-kinase/AKT signaling. CONCLUSIONS These results suggest a key role for MARCKS PSD in cancer disease and provide a unique strategy for inhibiting the activity of MARCKS PSD as a treatment for lung cancer.
Collapse
Affiliation(s)
- Ching-Hsien Chen
- 1 Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine and Center for Comparative Respiratory Biology and Medicine, University of California Davis, Davis, California; and
| | | | | | | | | | | | | |
Collapse
|
15
|
Lee S, Cho HY, Bui HTT, Kang D. The osteogenic or adipogenic lineage commitment of human mesenchymal stem cells is determined by protein kinase C delta. BMC Cell Biol 2014; 15:42. [PMID: 25420887 PMCID: PMC4258059 DOI: 10.1186/s12860-014-0042-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2014] [Accepted: 11/05/2014] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Mesenchymal stem cells (MSCs) have the potential to differentiate into specialized cell lineages such as osteoblasts and adipocytes in vitro. There exists a reciprocal relationship between osteogenic and adipogenic differentiation of MSCs that an osteogenic phenotype occurs at the expense of an adipogenic phenotype and vice versa, which in turn influence one another's phenotype through negative feedback loops. Thus, it is important to understand what signaling molecules modulate the lineage commitment of MSCs. Protein kinase C (PKC) plays a central role in cellular signal transduction for mediating diverse biological functions, and dysregulation of PKC activity is involved in various metabolic diseases including cancer, diabetes, and heart disease. Although the role of individual PKC isoforms has been investigated in various fields, the potential role of PKC in bone metabolism is not completely understood. In this study, we investigated the potential role of PKCδ in osteogenic lineage commitment of human bone marrow-derived mesenchymal stem cells (hBMSCs). RESULTS We observed that expression and phosphorylation of PKCδ were increased during osteogenic differentiation of hBMSCs. Pharmacological inhibition and genetic ablation of PKCδ in hBMSCs resulted in a significant attenuation of osteogenic differentiation as evidenced by reduced ALP activity and ECM mineralization, as well as down-regulation of the expression of osteoblast-specific genes. These effects were also accompanied by induction of adipogenic differentiation and up-regulation of the expression of adipocyte-specific genes involved in lipid synthesis in osteogenic induction of hBMSCs. Additionally, the activation of AMPK, which is a key cellular energy sensor, induced osteogenesis of hBMSCs. However, the inhibition of AMPK activity by compound C did not affect the activation of PKCδ at all, indicating that there is no direct correlation between AMPK and PKCδ in osteogenesis of hBMSCs. CONCLUSIONS These results suggest that PKCδ is a critical regulator for the balance between osteogenesis and adipogenesis of hBMSCs and thus has a potential novel therapeutic target for the treatment of metabolic bone diseases.
Collapse
|
16
|
Zhang Y, Shao G, Zhang W, Li S, Niu J, Hu D, Yang M, Ji X. Gabapentin inhibits central sensitization during migraine. Neural Regen Res 2014; 8:3003-12. [PMID: 25206620 PMCID: PMC4146212 DOI: 10.3969/j.issn.1673-5374.2013.32.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2013] [Accepted: 09/15/2013] [Indexed: 01/29/2023] Open
Abstract
Peripheral and central sensitizations are phenomena that occur during migraine. The role of pentin, a migraine preventive drug, on central sensitization remains unclear. In this study, a rat model of migraine was established by electrical stimulation of the trigeminal ganglion, and the an-imals were given intragastric gabapentin. Changes in amino acid content in the cerebrospinal fluid and protein kinase C membrane translocation in the spinal trigeminal nucleus were examined to clarify the mechanisms underlying the efficacy of gabapentin in the treatment of central sensitization during migraine. Electrophysiology, liquid chromatography-mass spectrometry and western blot analysis results revealed that gabapentin reduces neuronal excitability in the spinal nucleus in the trigeminal nerve, decreases excitatory amino acid content and inhibits the activation of protein ki-nase C. This provides evidence that excitatory amino acids and protein kinase C are involved in the formation and maintenance of central sensitization during migraine. Gabapentin inhibits migraine by reducing excitatory amino acid content in the cerebrospinal fluid and inhibiting protein kinase C ac-tivation.
Collapse
Affiliation(s)
- Yanbo Zhang
- Institute of Hypoxia Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100053, China ; Department of Neurology, Affiliated Hospital of Taishan Medical University, Tai'an 271000, Shandong Province, China
| | - Guo Shao
- Biomedical Research Center, Baotou Medical College, Baotou 014060, Inner Mongolia Autonomous Region, China
| | - Wei Zhang
- Department of Gastroenterology, Second Affiliated Hospital of Baotou Medical College, Baotou 014010, Inner Mongolia Autonomous Region, China
| | - Sijie Li
- Institute of Hypoxia Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
| | - Jingzhong Niu
- Department of Neurology, Affiliated Hospital of Taishan Medical University, Tai'an 271000, Shandong Province, China
| | - Dongmei Hu
- Department of Neurology, Affiliated Hospital of Taishan Medical University, Tai'an 271000, Shandong Province, China
| | - Mingfeng Yang
- Department of Neurology, Affiliated Hospital of Taishan Medical University, Tai'an 271000, Shandong Province, China
| | - Xunming Ji
- Institute of Hypoxia Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
| |
Collapse
|
17
|
Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma. Leukemia 2014; 29:715-26. [PMID: 25179733 DOI: 10.1038/leu.2014.255] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2014] [Revised: 08/08/2014] [Accepted: 08/14/2014] [Indexed: 12/27/2022]
Abstract
Multiple myeloma (MM) is incurable in virtually all patients due to the presence of innate and emergent drug-resistance. To identify potential drug resistance mechanisms in MM we used iTRAQ (isobaric tags for relative and absolute quantitation) mass spectrometry to compare protein expression profiles of drug-resistant (RPMI 8226-R5) and sensitive (RPMI 8226-S) isogenic cell lines. We identified selective overexpression of myristoylated alanine-rich C-kinase substrate (MARCKS) in drug-resistant R5 cells. MARCKS overexpression was also observed in several drug-resistant human myeloma cell lines (HMCLs) and in drug-resistant primary MM samples. Functionally, inhibition of MARCKS phosphorylation by enzastaurin or knockdown of the gene by RNAi significantly enhanced the sensitivity of resistant HMCLs and primary MM samples to bortezomib and to other anti-myeloma drugs, providing evidence that MARCKS can modulate drug response. Mechanistically, pMARCKS (phosphorylated form of MARCKS) was found to function as an E2F-1 cofactor to regulate SKP2 transcription. pMARCKS promoted cell-cycle progression by facilitating SKP2 expression, suppressing p27(Kip1) and potentially counteracting drug-induced cell-cycle arrest by promoting Cyclin E/CDK2 activity. Importantly, MARCKS knockdown in combination with bortezomib treatment overcame bortezomib resistance, significantly inhibited tumor growth and prolonged host survival in a MM xenograft model. These data provide a rationale for therapeutic targeting of pMARCKS to improve the outcome of patients with refractory/relapsed MM.
Collapse
|
18
|
Zhao X, Rotenberg SA. Phosphorylation of Cdc42 effector protein-4 (CEP4) by protein kinase C promotes motility of human breast cells. J Biol Chem 2014; 289:25844-54. [PMID: 25086031 DOI: 10.1074/jbc.m114.577783] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Cdc42 effector protein-4 (CEP4) was recently identified by our laboratory to be a substrate of multiple PKC isoforms in non-transformed MCF-10A human breast cells. The significance of phosphorylated CEP4 to PKC-stimulated motility of MCF-10A cells was evaluated. Single site mutants at Ser residues embedded in potential PKC consensus sites (Ser(18), Ser(77), Ser(80), and Ser(86)) were individually replaced with Asp residues to simulate phosphorylation. Following expression in weakly motile MCF-10A cells, the S18D and S80D mutants each promoted increased motility, and the double mutant (S18D/S80D) produced a stronger effect. MS/MS analysis verified that Ser(18) and Ser(80) were directly phosphorylated by PKCα in vitro. Phosphorylation of CEP4 severely diminished its affinity for Cdc42 while promoting Rac activation and formation of filopodia (microspikes). In contrast, the phosphorylation-resistant double mutant S18A/S80A-CEP4 blocked CEP4 phosphorylation and inhibited motility of MCF-10A cells that had been stimulated with PKC activator diacylglycerol lactone. In view of the dissociation of phospho-CEP4 from Cdc42, intracellular binding partners were explored by expressing each CEP4 double mutant from a tandem affinity purification vector followed by affinity chromatography, SDS-PAGE, and identification of protein bands evident only with S18D/S80D-CEP4. One binding partner was identified as tumor endothelial marker-4 (TEM4; ARHGEF17), a guanine nucleotide exchange factor that is involved in migration. In motile cells expressing S18D/S80D-CEP4, knockdown of TEM4 inhibited both Rac activation and motility. These findings support a model in which PKC-mediated phosphorylation of CEP4 at Ser(18) and Ser(80) causes its dissociation from Cdc42, thereby increasing its affinity for TEM4 and producing Rac activation, filopodium formation, and cell motility.
Collapse
Affiliation(s)
- Xin Zhao
- From the Department of Chemistry and Biochemistry, Queens College, Flushing, New York 11367 and The Graduate Center, The City University of New York, New York, New York 10016
| | - Susan A Rotenberg
- From the Department of Chemistry and Biochemistry, Queens College, Flushing, New York 11367 and
| |
Collapse
|
19
|
Chang FY, Brady SF. Characterization of an environmental DNA-derived gene cluster that encodes the bisindolylmaleimide methylarcyriarubin. Chembiochem 2014; 15:815-21. [PMID: 24648189 DOI: 10.1002/cbic.201300756] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2013] [Indexed: 01/11/2023]
Abstract
Bisindolylmaleimides represent a naturally occurring class of metabolites that are of interest because of their protein kinase inhibition activity. From a metagenomic library constructed with soil DNA, we identified the four gene mar cluster, a bisindolylmaleimide gene cluster that encodes for methylarcyriarubin (1) production. Heterologous expression of the mar gene cluster in E. coli revealed that the Rieske dioxygenase MarC facilitates the oxidative decarboxylation of a chromopyrrolic acid (CPA) intermediate to yield the bisindolylmaleimide core. The characterization of the mar cluster defines a new role for CPA in the biosynthesis of structurally diverse bacterial tryptophan dimers.
Collapse
Affiliation(s)
- Fang-Yuan Chang
- Laboratory of Genetically Encoded Small Molecules, Howard Hughes Medical Institute, The Rockefeller University, 1230 York Avenue, New York, NY 10065 (USA)
| | | |
Collapse
|
20
|
Irie K, Yanagita RC. Synthesis and Biological Activities of Simplified Analogs of the Natural PKC Ligands, Bryostatin-1 and Aplysiatoxin. CHEM REC 2014; 14:251-67. [DOI: 10.1002/tcr.201300036] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2013] [Indexed: 11/06/2022]
Affiliation(s)
- Kazuhiro Irie
- Division of Food Science and Biotechnology; Graduate School of Agriculture; Kyoto University; Kyoto 606-8502 Japan
| | - Ryo C. Yanagita
- Department of Applied Biological Science; Faculty of Agriculture, Kagawa University; Kagawa 761-0795 Japan
| |
Collapse
|
21
|
Specenier PM, Vermorken JB. Recurrent head and neck cancer: current treatment and future prospects. Expert Rev Anticancer Ther 2014; 8:375-91. [DOI: 10.1586/14737140.8.3.375] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
22
|
Mamidi N, Gorai S, Ravi B, Manna D. Physicochemical characterization of diacyltetrol-based lipids consisting of both diacylglycerol and phospholipid headgroups. RSC Adv 2014. [DOI: 10.1039/c4ra02495h] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Synthesis and physicochemical properties of a family of diacyltetrol-based hybrid lipids, containing both diacylglycerol and anionic lipid headgroups within the same moiety, have been reported for the first time.
Collapse
Affiliation(s)
- Narsimha Mamidi
- Department of Chemistry
- Indian Institute of Technology Guwahati
- , India
| | - Sukhamoy Gorai
- Department of Chemistry
- Indian Institute of Technology Guwahati
- , India
| | - Bolledu Ravi
- Department of Chemical Engineering
- Indian Institute of Technology Guwahati
- , India
| | - Debasis Manna
- Department of Chemistry
- Indian Institute of Technology Guwahati
- , India
| |
Collapse
|
23
|
Saha T, Maitra R, Chattopadhyay SK. A unified approach to the important protein kinase inhibitor balanol and a proposed analogue. Beilstein J Org Chem 2013; 9:2910-5. [PMID: 24454570 PMCID: PMC3896276 DOI: 10.3762/bjoc.9.327] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2013] [Accepted: 11/07/2013] [Indexed: 11/26/2022] Open
Abstract
A common approach to the important protein kinase inhibitor (−)-balanol and an azepine-ring-modified balanol derivative has been developed using an efficient fragment coupling protocol which proceeded in good overall yield.
Collapse
Affiliation(s)
- Tapan Saha
- Department of Chemistry, University of Kalyani, Kalyani - 741235, West Bengal, India
| | - Ratnava Maitra
- Department of Chemistry, University of Kalyani, Kalyani - 741235, West Bengal, India
| | | |
Collapse
|
24
|
Chen X, Wu Q, Tan L, Porter D, Jager MJ, Emery C, Bastian BC. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene 2013; 33:4724-34. [PMID: 24141786 DOI: 10.1038/onc.2013.418] [Citation(s) in RCA: 149] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2013] [Revised: 08/14/2013] [Accepted: 08/15/2013] [Indexed: 12/14/2022]
Abstract
Uveal melanoma (UM) is a genetically and biologically distinct type of melanoma, and once metastatic there is no effective treatment currently available. Eighty percent of UMs harbor mutations in the Gαq family members GNAQ and GNA11. Understanding the effector pathways downstream of these oncoproteins is important to identify opportunities for targeted therapy. We report consistent activation of the protein kinase C (PKC) and MAPK pathways as a consequence of GNAQ or GNA11 mutation. PKC inhibition with AEB071 or AHT956 suppressed PKC and MAPK signalling and induced G1 arrest selectively in melanoma cell lines carrying GNAQ or GNA11 mutations. In contrast, treatment with two different MEK inhibitors, PD0325901 and MEK162, inhibited the proliferation of melanoma cell lines irrespective of their mutation status, indicating that in the context of GNAQ or GNA11 mutation MAPK activation can be attributed to activated PKC. AEB071 significantly slowed the growth of tumors in an allograft model of GNAQ(Q209L)-transduced melanocytes, but did not induce tumor shrinkage. In vivo and in vitro studies showed that PKC inhibitors alone were unable to induce sustained suppression of MAP-kinase signaling. However, combinations of PKC and MEK inhibition, using either PD0325901or MEK162, led to sustained MAP-kinase pathway inhibition and showed a strong synergistic effect in halting proliferation and in inducing apoptosis in vitro. Furthermore, combining PKC and MEK inhibition was efficacious in vivo, causing marked tumor regression in a UM xenograft model. Our data identify PKC as a rational therapeutic target for melanoma patients with GNAQ or GNA11 mutations and demonstrate that combined MEK and PKC inhibition is synergistic, with superior efficacy compared to treatment with either approach alone.
Collapse
Affiliation(s)
- X Chen
- 1] Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA [2] Departments of Dermatology and Pathology, and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA
| | - Q Wu
- Departments of Dermatology and Pathology, and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA
| | - L Tan
- Novartis Institutes for BioMedical Research, Novartis, Cambridge, MA, USA
| | - D Porter
- Novartis Institutes for BioMedical Research, Novartis, Cambridge, MA, USA
| | - M J Jager
- Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands
| | - C Emery
- Novartis Institutes for BioMedical Research, Novartis, Cambridge, MA, USA
| | - B C Bastian
- 1] Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA [2] Departments of Dermatology and Pathology, and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA
| |
Collapse
|
25
|
Al-Alem LF, McCord LA, Southard RC, Kilgore MW, Curry TE. Activation of the PKC pathway stimulates ovarian cancer cell proliferation, migration, and expression of MMP7 and MMP10. Biol Reprod 2013; 89:73. [PMID: 23843242 DOI: 10.1095/biolreprod.112.102327] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Postmenopausal women are at a higher risk of ovarian cancer due, in part, to increased levels of gonadotropins such as luteinizing hormone (LH). Gonadotropins and other stimuli are capable of activating two pathways, PKA and PKC, that are altered in ovarian cancer. To determine the role of LH on ovarian cancer, we explored the effects of human chorionic gonadotropin (hCG), an LH mimic, and an activator of the PKC pathway, phorbol-12-myristate 13-acetate (PMA), on ovarian cancer cell-cycle kinetics and apoptosis in Ovcar3 cells. PMA treatment increased cells in the S phase of the cell cycle and initially increased apoptosis after 4 h before diminishing apoptosis after 8 h. Treatment of ovarian cancer cells with hCG had no effect on these parameters. The PKC pathway is known to differentially regulate matrix metalloproteinase (MMP) expression. Results showed that ovarian cancer cells treated with PMA increased MMP7 and MMP10 mRNA levels after 8 h of treatment, and expression remained high after 12 h before decreasing at 24 h. The mRNA expression of extracellular matrix metalloproteinase inducer (BSG), an activator of MMPs, was unaffected by PMA. Due to the role that MMPs play in migration, we investigated the effect of PMA activation of MMPs on ovarian cancer cell migration. The use of the MMP inhibitor GM6001 blocked the increased migratory effects of PMA on ovarian cancer cells. Together, these studies show that activating the PKC pathway causes significant changes in cell cycle kinetics and selective expression of MMPs that are involved in enhancing ovarian cancer cell proliferation and migration.
Collapse
Affiliation(s)
- Linah F Al-Alem
- Department of Molecular and Biomedical Pharmacology, University of Kentucky College of Medicine, Lexington, Kentucky
| | | | | | | | | |
Collapse
|
26
|
Chen CH, Thai P, Yoneda K, Adler KB, Yang PC, Wu R. A peptide that inhibits function of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis. Oncogene 2013; 33:3696-706. [PMID: 23955080 DOI: 10.1038/onc.2013.336] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2013] [Revised: 07/04/2013] [Accepted: 07/07/2013] [Indexed: 12/25/2022]
Abstract
Myristoylated Alanine-Rich C Kinase Substrate (MARCKS), a substrate of protein kinase C, is a key regulatory molecule controlling mucus granule secretion by airway epithelial cells as well as directed migration of leukocytes, stem cells and fibroblasts. Phosphorylation of MARKCS may be involved in these responses. However, the functionality of MARCKS and its related phosphorylation in lung cancer malignancy have not been characterized. This study demonstrated elevated levels of MARCKS and phospho-MARCKS in highly invasive lung cancer cell lines and lung cancer specimens from non-small-cell lung cancer patients. siRNA knockdown of MARCKS expression in these highly invasive lung cancer cell lines reduced cell migration and suppressed PI3K (phosphatidylinositol 3'-kinase)/Akt phosphorylation and Slug level. Interestingly, treatment with a peptide identical to the MARCKS N-terminus sequence (the MANS peptide) impaired cell migration in vitro and also the metastatic potential of invasive lung cancer cells in vivo. Mechanistically, MANS peptide treatment resulted in a coordination of increase of E-cadherin expression, suppression of MARCKS phosphorylation and AKT/Slug signalling pathway but not the expression of total MARCKS. These results indicate a crucial role for MARCKS, specifically its phosphorylated form, in potentiating lung cancer cell migration/metastasis and suggest a potential use of MARCKS-related peptides in the treatment of lung cancer metastasis.
Collapse
Affiliation(s)
- C-H Chen
- Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine and Center for Comparative Respiratory Biology and Medicine, University of California Davis, Davis, CA, USA
| | - P Thai
- Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine and Center for Comparative Respiratory Biology and Medicine, University of California Davis, Davis, CA, USA
| | - K Yoneda
- Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine and Center for Comparative Respiratory Biology and Medicine, University of California Davis, Davis, CA, USA
| | - K B Adler
- Department of Molecular Biomedical Sciences, North Carolina State University, Raleigh, NC, USA
| | - P-C Yang
- Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
| | - R Wu
- Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine and Center for Comparative Respiratory Biology and Medicine, University of California Davis, Davis, CA, USA
| |
Collapse
|
27
|
Absolute quantitation of endogenous proteins with precision and accuracy using a capillary Western system. Anal Biochem 2013; 442:97-103. [PMID: 23896461 DOI: 10.1016/j.ab.2013.07.022] [Citation(s) in RCA: 76] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2013] [Revised: 07/13/2013] [Accepted: 07/16/2013] [Indexed: 11/20/2022]
Abstract
Precise and accurate quantification of protein expression levels in a complex biological setting is challenging. Here, we describe a method for absolute quantitation of endogenous proteins in cell lysates using an automated capillary immunoassay system, the size-based Simple Western system (recently developed by ProteinSimple). The method was able to accurately measure the absolute amounts of target proteins at picogram or sub-picogram levels per nanogram of cell lysates. The measurements were independent of the cell matrix or the cell lysis buffer and were not affected by different antibody affinities for their specific epitopes. We then applied this method to quantitate absolute levels of expression of protein kinase C (PKC) isoforms in LNCaP and U937 cells, two cell lines used extensively for probing the downstream biological responses to PKC targeted ligands. Our absolute quantitation confirmed the predominance of PKCδ in both cells, supporting the important functional role of this PKC isoform in these cell lines. The method described here provides an approach to accurately quantitate levels of protein expression and correlate protein level with function. In addition to enhanced accuracy relative to conventional Western analysis, it circumvents the distortions inherent in comparison with signal intensities from different antibodies with different affinities.
Collapse
|
28
|
Pachl F, Plattner P, Ruprecht B, Médard G, Sewald N, Kuster B. Characterization of a chemical affinity probe targeting Akt kinases. J Proteome Res 2013; 12:3792-800. [PMID: 23795919 DOI: 10.1021/pr400455j] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Protein kinases are key regulators of cellular processes, and aberrant function is often associated with human disease. Consequently, kinases represent an important class of therapeutic targets and about 20 kinase inhibitors (KIs) are in clinical use today. Detailed knowledge about the selectivity of KIs is important for the correct interpretation of their pharmacological and systems biological effects. Chemical proteomic approaches for systematic kinase inhibitor selectivity profiling have emerged as important molecular tools in this regard, but the coverage of the human kinome is still incomplete. Here, we describe a new affinity probe targeting Akt and many other members of the AGC kinase family that considerably extends the scope of KI profiling by chemical proteomics. In combination with the previously published kinobeads, the synthesized probe was applied to selectivity profiling of the Akt inhibitors GSK690693 and GSK2141795 in human cancer cells. The results confirmed the inhibition of all Akt isoforms and of a number of known as well as CDC42BPB as a novel putative target for GSK690693. This work also established, for the first time, the kinase selectivity profile of the clinical phase I drug GSK2141795 and identified PRKG1 as a low nanomolar kinase target as well as the ATP-dependent 5'-3' DNA helicase ERCC2 as a potential new non-kinase off-target.
Collapse
Affiliation(s)
- Fiona Pachl
- Chair for Proteomics and Bioanalytics, Center of Life and Food Sciences Weihenstephan, Technische Universität München, Emil-Erlenmeyer-Forum 5, 85354 Freising, Germany
| | | | | | | | | | | |
Collapse
|
29
|
Sobhia ME, Grewal BK, Paul MLS, Patel J, Kaur A, Haokip T, Kokkula A. Protein kinase C inhibitors: a patent review (2010 – present). Expert Opin Ther Pat 2013; 23:1451-68. [DOI: 10.1517/13543776.2013.812073] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
30
|
Kamachi H, Tanaka K, Yanagita RC, Murakami A, Murakami K, Tokuda H, Suzuki N, Nakagawa Y, Irie K. Structure–activity studies on the side chain of a simplified analog of aplysiatoxin (aplog-1) with anti-proliferative activity. Bioorg Med Chem 2013; 21:2695-702. [DOI: 10.1016/j.bmc.2013.03.013] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2013] [Revised: 03/13/2013] [Accepted: 03/14/2013] [Indexed: 11/25/2022]
|
31
|
Kedei N, Lewin NE, Géczy T, Selezneva J, Braun DC, Chen J, Herrmann MA, Heldman MR, Lim L, Mannan P, Garfield SH, Poudel YB, Cummins TJ, Rudra A, Blumberg PM, Keck GE. Biological profile of the less lipophilic and synthetically more accessible bryostatin 7 closely resembles that of bryostatin 1. ACS Chem Biol 2013; 8:767-77. [PMID: 23369356 DOI: 10.1021/cb300671s] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The bryostatins are a group of 20 macrolides isolated by Pettit and co-workers from the marine organism Bugula neritina. Bryostatin 1, the flagship member of the family, has been the subject of intense chemical and biological investigations due to its remarkably diverse biological activities, including promising indications as therapy for cancer, Alzheimer's disease, and HIV. Other bryostatins, however, have attracted far less attention, most probably due to their relatively low natural abundance and associated scarcity of supply. Among all macrolides in this family, bryostatin 7 is biologically the most potent protein kinase C (PKC) ligand (in terms of binding affinity) and also the first bryostatin to be synthesized in the laboratory. Nonetheless, almost no biological studies have been carried out on this agent. We describe herein the total synthesis of bryostatin 7 based on our pyran annulation technology, which allows for the first detailed biological characterizations of bryostatin 7 with side-by-side comparisons to bryostatin 1. The results suggest that the more easily synthesized and less lipophilic bryostatin 7 may be an effective surrogate for bryostatin 1.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Yam B. Poudel
- Department of Chemistry, University of Utah, 315 South 1400 East, RM 2020, Salt
Lake City, Utah 84112, United States
| | - Thomas J. Cummins
- Department of Chemistry, University of Utah, 315 South 1400 East, RM 2020, Salt
Lake City, Utah 84112, United States
| | - Arnab Rudra
- Department of Chemistry, University of Utah, 315 South 1400 East, RM 2020, Salt
Lake City, Utah 84112, United States
| | | | - Gary E. Keck
- Department of Chemistry, University of Utah, 315 South 1400 East, RM 2020, Salt
Lake City, Utah 84112, United States
| |
Collapse
|
32
|
Menne J, Shushakova N, Bartels J, Kiyan Y, Laudeley R, Haller H, Park JK, Meier M. Dual inhibition of classical protein kinase C-α and protein kinase C-β isoforms protects against experimental murine diabetic nephropathy. Diabetes 2013; 62:1167-74. [PMID: 23434935 PMCID: PMC3609593 DOI: 10.2337/db12-0534] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Abstract
Activation of protein kinase C (PKC) has been implicated in the pathogenesis of diabetic nephropathy with proteinuria and peritubular extracellular matrix production. We have previously shown that the PKC isoforms α and β mediate different cellular effects. PKC-β contributes to hyperglycemia-induced renal matrix production, whereby PKC-α is involved in the development of albuminuria. We further tested this hypothesis by deletion of both isoforms and used a PKC inhibitor. We analyzed the phenotype of nondiabetic and streptozotocin (STZ)-induced diabetic homozygous PKC-α/β double-knockout mice (PKC-α/β(-/-)). After 8 weeks of diabetes mellitus, the high-glucose-induced renal and glomerular hypertrophy as well as transforming growth factor-β1) and extracellular matrix production were diminished in the PKC-α/β(-/-) mice compared with wild-type controls. Urinary albumin/creatinine ratio also was significantly reduced, however, it was not completely abolished in diabetic PKC-α/β(-/-) mice. Treatment with CGP41252, which inhibits PKC-α and PKC-β, is able to prevent the development of albuminuria and to reduce existing albuminuria in type 1 (STZ model) or type 2 (db/db model) diabetic mice. These results support our hypothesis that PKC-α and PKC-β contribute to the pathogenesis of diabetic nephropathy, and that dual inhibition of the classical PKC isoforms is a suitable therapeutic strategy in the prevention and treatment of diabetic nephropathy.
Collapse
Affiliation(s)
- Jan Menne
- Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
- Phenos GmbH, Hannover, Germany
- Corresponding authors: Jan Menne, , and Hermann Haller,
| | - Nelli Shushakova
- Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
- Phenos GmbH, Hannover, Germany
| | - Janina Bartels
- Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
| | - Yulia Kiyan
- Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
| | - Robert Laudeley
- Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
| | - Hermann Haller
- Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
- Corresponding authors: Jan Menne, , and Hermann Haller,
| | - Joon-Keun Park
- Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
| | - Matthias Meier
- Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
| |
Collapse
|
33
|
Abstract
Protein kinase C (PKC) has been a tantalizing target for drug discovery ever since it was first identified as the receptor for the tumour promoter phorbol ester in 1982. Although initial therapeutic efforts focused on cancer, additional indications--including diabetic complications, heart failure, myocardial infarction, pain and bipolar disorder--were targeted as researchers developed a better understanding of the roles of eight conventional and novel PKC isozymes in health and disease. Unfortunately, both academic and pharmaceutical efforts have yet to result in the approval of a single new drug that specifically targets PKC. Why does PKC remain an elusive drug target? This Review provides a short account of some of the efforts, challenges and opportunities in developing PKC modulators to address unmet clinical needs.
Collapse
|
34
|
Lin SC, Chen WY, Lin KY, Chen SH, Chang CC, Lin SE, Fang CL. Clinicopathological correlation and prognostic significance of protein kinase cα overexpression in human gastric carcinoma. PLoS One 2013; 8:e56675. [PMID: 23468872 PMCID: PMC3582558 DOI: 10.1371/journal.pone.0056675] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2012] [Accepted: 01/16/2013] [Indexed: 01/24/2023] Open
Abstract
OBJECTIVES This study investigated the PKCα protein expression in gastric carcinoma, and correlated it with clinicopathological parameters. The prognostic significance of PKCα protein expression in gastric carcinoma was analyzed. METHODS Quantitative real-time PCR test was applied to compare the PKCα mRNA expression in tumorous and nontumorous tissues of gastric carcinoma in ten randomly selected cases. Then PKCα protein expression was evaluated in 215 cases of gastric carcinoma using immunohistochemical method. The immunoreactivity was scored semiquantitatively as: 0 = absent; 1 = weak; 2 = moderate; and 3 = strong. All cases were further classified into two groups, namely PKCα overexpression group with score 2 or 3, and non-overexpression group with score 0 or 1. The PKCα protein expression was correlated with clinicopathological parameters. Survival analysis was performed to determine the prognostic significance of PKCα protein expression in patients with gastric carcinoma. RESULTS PKCα mRNA expression was upregulated in all ten cases of gastric carcinoma via quantitative real-time PCR test. In immunohistochemical study, eighty-eight out of 215 cases (41%) of gastric carcinoma revealed PKCα protein overexpression, which was statistically correlated with age (P = 0.0073), histologic type (P<0.0001), tumor differentiation (P = 0.0110), depth of invasion (P = 0.0003), angiolymphatic invasion (P = 0.0373), pathologic stage (P = 0.0047), and distant metastasis (P = 0.0048). We found no significant difference in overall and disease free survival rates between PKCα overexpression and non-overexpression groups (P = 0.0680 and 0.0587). However, PKCα protein overexpression emerged as a significant independent prognostic factor in multivariate Cox regression analysis (hazard ratio 0.632, P = 0.0415). CONCLUSIONS PKCα protein is upregulated in gastric carcinoma. PKCα protein expression is statistically correlated with age, histologic type, tumor differentiation, depth of invasion, angiolymphatic invasion, pathologic stage, and distant metastasis. The PKCα protein overexpression in patients with gastric carcinoma is a significant independent prognostic factor in multivariate Cox regression analysis.
Collapse
Affiliation(s)
- Shee-Chan Lin
- Division of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan
| | - Wei-Yu Chen
- Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
- Department of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
| | - Kai-Yuan Lin
- Department of Medical Research, Chi-Mei Medical Center, Tainan, Taiwan
- Department of Biotechnology, Chia Nan University of Pharmacy and Science, Tainan, Taiwan
| | - Sheng-Hsuan Chen
- Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
- Division of Gastroenterology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan
| | - Chun-Chao Chang
- Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
- Division of Gastroenterology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan
| | - Sey-En Lin
- Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
- Department of Pathology, Taipei Medical University Hospital, Taipei, Taiwan
| | - Chia-Lang Fang
- Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
- Department of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
| |
Collapse
|
35
|
PKC activation by resveratrol derivatives with unsaturated aliphatic chain. PLoS One 2012; 7:e52888. [PMID: 23285216 PMCID: PMC3528653 DOI: 10.1371/journal.pone.0052888] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2012] [Accepted: 11/22/2012] [Indexed: 01/04/2023] Open
Abstract
Resveratrol (1) is a naturally occurring phytoalexin that affects a variety of human disease models, including cardio- and neuroprotection, immune regulation, and cancer chemoprevention. One of the possible mechanisms by which resveratrol affects these disease states is by affecting the cellular signaling network involving protein kinase C (PKC). PKC is the family of serine/threonine kinases, whose activity is inhibited by resveratrol. To develop PKC isotype selective molecules on the resveratrol scaffold, several analogs (2–5) of resveratrol with a long aliphatic chain varying with number of unsaturated doubled bonds have been synthesized, their cytotoxic effects on CHO-K1 cells are measured and their effects on the membrane translocation properties of PKCα and PKCε have been determined. The analogs showed less cytotoxic effects on CHO-K1 cells. Analog 4 with three unsaturated double bonds in its aliphatic chain activated PKCα, but not PKCε. Analog 4 also activated ERK1/2, the downstream proteins in the PKC signaling pathway. Resveratrol analogs 2–5, however, did not show any inhibition of the phorbol ester-induced membrane translocation for either PKCα or PKCε. Molecular docking of 4 into the activator binding site of PKCα revealed that the resveratrol moiety formed hydrogen bonds with the activator binding residues and the aliphatic chain capped the activator binding loops making its surface hydrophobic to facilitate its interaction with the plasma membrane. The present study shows that subtle changes in the resveratrol structure can have profound impact on the translocation properties of PKCs. Therefore, resveratrol scaffold can be used to develop PKC selective modulators for regulating associated disease states.
Collapse
|
36
|
Chen X, Zhao X, Abeyweera TP, Rotenberg SA. Analysis of substrates of protein kinase C isoforms in human breast cells by the traceable kinase method. Biochemistry 2012; 51:7087-97. [PMID: 22897107 DOI: 10.1021/bi300999c] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A previous report [Abeyweera, T. P., and Rotenberg, S. A. (2007) Biochemistry 46, 2364-2370] described the application of the traceable kinase method in identifying substrates of protein kinase Cα (PKC-α) in nontransformed human breast MCF-10A cells. Here, a nonradioactive variation of this method compared the phosphoprotein profiles of three traceable PKC isoforms (α, δ, and ζ) for the purpose of identifying novel, isoform-selective substrates. Each FLAG-tagged traceable kinase was expressed and co-immunoprecipitated along with high-affinity substrates. The isolated kinase and its associated substrates were subjected to an in vitro phosphorylation reaction with traceable kinase-specific N(6)-phenyl-ATP, and the resulting phosphoproteins were analyzed by Western blotting with an antibody that recognizes the phosphorylated PKC consensus site. Phosphoprotein profiles generated by PKC-α and -δ were similar and differed markedly from that of PKC-ζ. Mass spectrometry of selected bands revealed known PKC substrates and several potential substrates that included the small GTPase-associated Cdc42 effector protein-4 (CEP4). Of those potential substrates tested, only CEP4 was phosphorylated by pure PKC-α, -δ, and -ζ isoforms in vitro, and by endogenous PKC isoforms in MCF-10A cells treated with DAG-lactone, a membrane permeable PKC activator. Under these conditions, the stoichiometry of CEP4 phosphorylation was 3.2 ± 0.5 (moles of phospho-CEP4 per mole of CEP4). Following knockdown with isoform-specific shRNA-encoding plasmids, the level of phosphorylation of CEP4 was substantially decreased in response to silencing of each of the three isoforms (PKC-α, -δ, and -ζ), whereas testing of kinase-dead mutants supported a role for only PKC-α and -δ in CEP4 phosphorylation. These findings identify CEP4 as a novel intracellular PKC substrate that is phosphorylated by multiple PKC isoforms.
Collapse
Affiliation(s)
- Xiangyu Chen
- Department of Chemistry and Biochemistry, Queens College, The City University of New York, 65-30 Kissena Boulevard, Flushing, NY 11367, USA
| | | | | | | |
Collapse
|
37
|
Kikumori M, Yanagita RC, Tokuda H, Suzuki N, Nagai H, Suenaga K, Irie K. Structure–Activity Studies on the Spiroketal Moiety of a Simplified Analogue of Debromoaplysiatoxin with Antiproliferative Activity. J Med Chem 2012; 55:5614-26. [DOI: 10.1021/jm300566h] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Masayuki Kikumori
- Division of
Food Science and
Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto 606-8502, Japan
| | - Ryo C. Yanagita
- Division of
Food Science and
Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto 606-8502, Japan
- Department of Applied Biological
Science, Faculty of Agriculture, Kagawa University, Kagawa 761-0795, Japan
| | - Harukuni Tokuda
- Department of Complementary and Alternative Medicine, Clinical R&D, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8640, Japan
| | - Nobutaka Suzuki
- Department of Complementary and Alternative Medicine, Clinical R&D, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8640, Japan
| | - Hiroshi Nagai
- Department
of Ocean Sciences, Tokyo University of Marine Science and Technology,
Tokyo 108-8477, Japan
| | - Kiyotake Suenaga
- Faculty
of Science and Technology, Keio University, Yokohama 223-8522, Japan
| | - Kazuhiro Irie
- Division of
Food Science and
Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto 606-8502, Japan
| |
Collapse
|
38
|
Carter CA, Misra M, Pelech S. Proteomic analyses of lung lysates from short-term exposure of Fischer 344 rats to cigarette smoke. J Proteome Res 2011; 10:3720-31. [PMID: 21627322 DOI: 10.1021/pr200345y] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A short-term 5 day mainstream cigarette smoke exposure study was conducted in Fischer 344 rats to identify changes in lung proteins. Groups of 10 male and female rats at 5 weeks of age were assigned to one of four exposure groups. Animals received either nose-only filtered air (Air Control) or 75, 200, or 400 mg total particulate matter (TPM)/m(3) of diluted cigarette smoke. Exposures were conducted for 3 h per day, for 5 consecutive days. One lung per animal was frozen in liquid nitrogen and processed for proteomic analyses. Lung lysates from control verses treated animals were screened with 650 antibodies for changes in signaling protein levels and phosphorylation using antibody microarray technology, and then over 100 of the top protein hits were assessed by immunoblotting. The top smoke-altered proteins were further evaluated using reverse lysate microarrays. Major protein changes showed medium to strong bands on Western blots, depended on dose and gender, and included protein-serine kinases (Cot/Tpl2, ERK1/2, GSK3α/β, MEK6, PKCα/γ, RSK1), protein phosphatases (PP4/A'2, PP1Cβ), and other proteins (caspase 5, CRMP2, Hsc70, Hsp60, Rac1 and STAT2). The most pronounced changes occurred with 75 mg TPM/m(3) exposed females and 200 mg TPM/m(3) exposed males. Smoke-altered proteins regulate apoptosis, stress response, cell structure, and inflammation. Changes in identified proteins may serve as early indicators of lung damage.
Collapse
Affiliation(s)
- Charleata A Carter
- A. W. Spears Research Center, 420 N. English Street, Lorillard Tobacco Company, Greensboro, North Carolina 27405, USA
| | | | | |
Collapse
|
39
|
Bekhite MM, Finkensieper A, Binas S, Müller J, Wetzker R, Figulla HR, Sauer H, Wartenberg M. VEGF-mediated PI3K class IA and PKC signaling in cardiomyogenesis and vasculogenesis of mouse embryonic stem cells. J Cell Sci 2011; 124:1819-30. [PMID: 21540297 DOI: 10.1242/jcs.077594] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
VEGF-, phosphoinositide 3-kinase (PI3K)- and protein kinase C (PKC)-regulated signaling in cardiac and vascular differentiation was investigated in mouse ES cells and in ES cell-derived Flk-1⁺ cardiovascular progenitor cells. Inhibition of PI3K by wortmannin and LY294002, disruption of PI3K catalytic subunits p110α and p110δ using short hairpin RNA (shRNA), or inhibition of p110α with compound 15e and of p110δ with IC-87114 impaired cardiac and vascular differentiation. By contrast, TGX-221, an inhibitor of p110β, and shRNA knockdown of p110β were without significant effects. Antagonists of the PKC family, i.e. bisindolylmaleimide-1 (BIM-1), GÖ 6976 (targeting PKCα/βII) and rottlerin (targeting PKCδ) abolished vasculogenesis, but not cardiomyogenesis. Inhibition of Akt blunted cardiac as well as vascular differentiation. VEGF induced phosphorylation of PKCα/βII and PKCδ but not PKCζ. This was abolished by PI3K inhibitors and the VEGFR-2 antagonist SU5614. Furthermore, phosphorylation of Akt and phosphoinositide-dependent kinase-1 (PDK1) was blunted upon inhibition of PI3K, but not upon inhibition of PKC by BIM-1, suggesting that activation of Akt and PDK1 by VEGF required PI3K but not PKC. In summary, we demonstrate that PI3K catalytic subunits p110α and p110δ are central to cardiovasculogenesis of ES cells. Akt downstream of PI3K is involved in both cardiomyogenesis and vasculogenesis, whereas PKC is involved only in vasculogenesis.
Collapse
Affiliation(s)
- Mohamed M Bekhite
- Department of Internal Medicine I, Cardiology Division, Friedrich Schiller University, 07743 Jena, Germany
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Nakura A, Higuchi C, Yoshida K, Yoshikawa H. PKCα suppresses osteoblastic differentiation. Bone 2011; 48:476-84. [PMID: 20951242 DOI: 10.1016/j.bone.2010.09.238] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2010] [Revised: 09/08/2010] [Accepted: 09/29/2010] [Indexed: 11/30/2022]
Abstract
Protein kinase C (PKC) plays an essential role in cellular signal transduction for mediating a variety of biological functions. There are 11 PKC isoforms and these isoforms are believed to play distinct roles in cells. Although the role of individual isoforms of PKC has been investigated in many fields, little is known about the role of PKC in osteoblastic differentiation. Here, we investigated which isoforms of PKC are involved in osteoblastic differentiation of the mouse preosteoblastic cell line MC3T3-E1. Treatment with Gö6976, an inhibitor of PKCα and PKCβI, increased alkaline phosphatase (ALP) activity as well as gene expression of ALP and Osteocalcin (OCN), and enhanced calcification of the extracellular matrix. Concurrently, osteoblastic cell proliferation decreased at a concentration of 1.0 μM. In contrast, a PKCβ inhibitor, which inhibits PKCβI and PKCβII, did not significantly affect osteoblastic differentiation or cell proliferation. Knockdown of PKCα using MC3T3-E1 cells transfected with siRNA also induced an increase in ALP activity and in gene expression of ALP and OCN. In contrast, overexpression of wild-type PKCα decreased ALP activity and attenuated osteoblastic differentiation markers including ALP and OCN, but promoted cell proliferation. Taken together, our results indicate that PKCα suppresses osteoblastic differentiation, but promotes osteoblastic cell proliferation. These results imply that PKCα may have a pivotal role in cell signaling that modulates the differentiation and proliferation of osteoblasts.
Collapse
Affiliation(s)
- Akio Nakura
- Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
| | | | | | | |
Collapse
|
41
|
Protein kinase C: an attractive target for cancer therapy. Cancers (Basel) 2011; 3:531-67. [PMID: 24212628 PMCID: PMC3756376 DOI: 10.3390/cancers3010531] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2010] [Revised: 01/19/2011] [Accepted: 01/26/2011] [Indexed: 12/21/2022] Open
Abstract
Apoptosis plays an important role during all stages of carcinogenesis and the development of chemoresistance in tumor cells may be due to their selective defects in the intracellular signaling proteins, central to apoptotic pathways. Consequently, many studies have focused on rendering the chemotherapy more effective in order to prevent chemoresistance and pre-clinical and clinical data has suggested that protein kinase C (PKC) may represent an attractive target for cancer therapy. Therefore, a complete understanding of how PKC regulates apoptosis and chemoresistance may lead to obtaining a PKC-based therapy that is able to reduce drug dosages and to prevent the development of chemoresistance.
Collapse
|
42
|
Totoń E, Ignatowicz E, Skrzeczkowska K, Rybczyńska M. Protein kinase Cε as a cancer marker and target for anticancer therapy. Pharmacol Rep 2011; 63:19-29. [DOI: 10.1016/s1734-1140(11)70395-4] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2010] [Revised: 06/10/2010] [Indexed: 01/23/2023]
|
43
|
Irie K, Yanagita RC, Nakagawa Y. Challenges to the development of bryostatin-type anticancer drugs based on the activation mechanism of protein kinase Cδ. Med Res Rev 2010; 32:518-35. [DOI: 10.1002/med.20220] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Kazuhiro Irie
- Division of Food Science and Biotechnology; Graduate School of Agriculture; Kyoto University; Kitashirakawa Oiwake-cho, Sakyo-ku Kyoto Japan
| | - Ryo C. Yanagita
- Division of Food Science and Biotechnology; Graduate School of Agriculture; Kyoto University; Kitashirakawa Oiwake-cho, Sakyo-ku Kyoto Japan
| | - Yu Nakagawa
- Synthetic Cellular Chemistry Laboratory; Advanced Science Institute; RIKEN; Wako-shi Saitama Japan
| |
Collapse
|
44
|
Jia Y, Lin J, Zeng W, Zhang C. Effect of prostaglandin on luteinizing hormone-stimulated proliferation of theca externa cells from chicken prehierarchical follicles. Prostaglandins Other Lipid Mediat 2010; 92:77-84. [PMID: 20381633 DOI: 10.1016/j.prostaglandins.2010.03.005] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2010] [Revised: 03/16/2010] [Accepted: 03/31/2010] [Indexed: 01/01/2023]
Abstract
The effect of prostaglandin (PG) on proliferation of chicken theca externa cells from prehierarchical small yellow follicles (SYF) was evaluated and involved signaling pathways as well as mRNA expression of cAMP response element binding protein (CREB1), cyclins (CCND1 and CCNE1) and cyclin-dependent kinases (CDKs) were investigated. Results showed that PGE(1) (1-100 ng/ml) manifested a similar proliferating effect as LH on theca externa cells, and this stimulating effect was restrained by the prostaglandin receptor antagonist SC19220 at 10(-7) to 10(-5)M. Moreover, prostaglandin synthase inhibitor indomethacin (10(-7) to 10(-5)M) suppressed LH-induced increase in the cell number. In addition, PGE(1)-stimulated cell proliferation was also predominantly hindered by H(89) (PKA inhibitor) instead of H(7) (PKC inhibitor). Meanwhile, BrdU incorporation experiment displayed similar changes with the cell number. Furthermore, H(89), SC19220 and indomethacin abolished the PGE(1)-stimulated increase in the expression of CREB1, CCND1/CDK6 and CCNE1/CDK2 mRNAs, indicating that cAMP/PKA/CREB1 signaling cascade was involved in PGE(1)-stimulated DNA synthesis. In conclusion, PG could promote proliferation of theca externa cells from prehierarchical follicles through changes in cyclin D1/CDK6, cyclin E1/CDK2 and CREB1 mRNA expression via cAMP/PKA and CREB1 signaling cascade. These results suggest that PG may promote development of chicken prehierarchical follicles and is related to dominant follicle selection in laying hens.
Collapse
Affiliation(s)
- Yudong Jia
- Key Laboratory of Animal Epidemic Etiology & Immunological Prevention of the Ministry of Agriculture, Department of Veterinary Medicine, College of Animal Sciences, Zhejiang University, No. 268 Kaixuan Road, Hangzhou 310029, China
| | | | | | | |
Collapse
|
45
|
Michalski A, Bouffet E, Taylor RE, Hargrave D, Walker D, Picton S, Robinson K, Pizer B, Bujkiewicz S. The addition of high-dose tamoxifen to standard radiotherapy does not improve the survival of patients with diffuse intrinsic pontine glioma. J Neurooncol 2010; 100:81-8. [PMID: 20238235 DOI: 10.1007/s11060-010-0141-9] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2009] [Accepted: 02/07/2010] [Indexed: 10/19/2022]
Abstract
The study aimed to examine the tolerability of the combination of radiotherapy and tamoxifen and the effect on median and event free survival as well as collecting data on the use of steroids in this population. 31 patients with diffuse intrinsic pontine glioma, diagnosed on clinical and radiological criteria, were treated with high-dose oral tamoxifen (120 mg/m(2)/day) given concomitantly with standard dose radiotherapy (54 Gy in 1.8 Gy fractions over 6 weeks). Results Tamoxifen was well tolerated with no grade 3 or 4 CTC toxicity reported. At 1 year, the progression free and event free survival were 3.2% (95% CI: 0.2-14.1%), and at 6 months 19.4% (CI: 7.9% to 34.6%). The overall survival at 1 year was 16.1% (CI: 5.9-30.9%) with median survival 6.32 months. In this study, in which tamoxifen was used in conjunction with radiotherapy, progression free survival was shown to be less good when compared with historical data HR = 3.1 (CI: 1.7-5.7). There was no significant reduction in overall survival. The addition of high-dose tamoxifen, although well tolerated, confers no clinical benefit to patients treated with diffuse intrinsic pontine glioma treated with standard radiotherapy.
Collapse
Affiliation(s)
- Antony Michalski
- Department of Oncology, Great Ormond Street Hospital, London, WC1N 3JH, England, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Pan JJ, Kashemirov BA, Lee J, McKenna CE, Devlin FJ, Stephens PJ. Electronic circular dichroism of monomethyl [16O,17O,18O]-phosphate and [16O,17O,18O]-thiophosphate revisited. Bioorg Chem 2010; 38:7-16. [DOI: 10.1016/j.bioorg.2009.02.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2007] [Revised: 02/16/2009] [Accepted: 02/17/2009] [Indexed: 11/27/2022]
|
47
|
Meng XW, Heldebrant MP, Flatten KS, Loegering DA, Dai H, Schneider PA, Gomez TS, Peterson KL, Trushin SA, Hess AD, Smith BD, Karp JE, Billadeau DD, Kaufmann SH. Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy. J Biol Chem 2009; 285:888-902. [PMID: 19887445 DOI: 10.1074/jbc.m109.057638] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Although treatment with the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) is known to protect a subset of cells from induction of apoptosis by death ligands such as Fas ligand and tumor necrosis factor-alpha-related apoptosis-inducing ligand, the mechanism of this protection is unknown. This study demonstrated that protection in short term apoptosis assays and long term proliferation assays was maximal when Jurkat or HL-60 human leukemia cells were treated with 2-5 nm PMA. Immunoblotting demonstrated that multiple PKC isoforms, including PKCalpha, PKCbeta, PKCepsilon, and PKC, translocated from the cytosol to a membrane-bound fraction at these PMA concentrations. When the ability of short hairpin RNA (shRNA) constructs that specifically down-regulated each of these isoforms was examined, PKCbeta shRNA uniquely reversed PMA-induced protection against cell death. The PKCbeta-selective small molecule inhibitor enzastaurin had a similar effect. Although mass spectrometry suggested that Fas is phosphorylated on a number of serines and threonines, mutation of these sites individually or collectively had no effect on Fas-mediated death signaling or PMA protection. Further experiments demonstrated that PMA diminished ligand-induced cell surface accumulation of Fas and DR5, and PKCbeta shRNA or enzastaurin reversed this effect. Moreover, enzastaurin sensitized a variety of human tumor cell lines and clinical acute myelogenous leukemia isolates, which express abundant PKCbeta, to tumor necrosis factor-alpha related apoptosis-inducing ligand-induced death in the absence of PMA. Collectively, these results identify a specific PKC isoform that modulates death receptor-mediated cytotoxicity as well as a small molecule inhibitor that mitigates the inhibitory effects of PKC activation on ligand-induced death receptor trafficking and cell death.
Collapse
Affiliation(s)
- Xue Wei Meng
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Comin MJ, Czifra G, Kedei N, Telek A, Lewin NE, Kolusheva S, Velasquez JF, Kobylarz R, Jelinek R, Blumberg PM, Marquez VE. Conformationally constrained analogues of diacylglycerol (DAG). 31. Modulation of the biological properties of diacylgycerol lactones (DAG-lactones) containing rigid-rod acyl groups separated from the core lactone by spacer units of different lengths. J Med Chem 2009; 52:3274-83. [PMID: 19379015 PMCID: PMC2708097 DOI: 10.1021/jm900186m] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
![]()
Diacylglycerol lactones built with a rigid 4-[(methylphenyl)ethynyl]phenyl rod that is separated from the exocyclic acylcarbonyl of the DAG-lactone core by a spacer unit of variable length were synthesized and studied. Binding affinities for a panel of classical and novel PKC isozymes in two different phospholipid environments, one corresponding to the plasma membrane of cells, were determined. The kinetics and site of translocation for the PKC isozymes α and δ upon treatment with the compounds were also studied as well as the early response of ERK phosphorylation and the late response of induction of apoptosis in the human prostatic carcinoma cell line LNCaP. Finally, the compounds were evaluated in terms of their interaction with biomimetic lipid/polydiacetylene membranes by the associated chromatic response. The different spatial disposition of the rigid structural motif on the DAG-lactones contributes to differential activity.
Collapse
Affiliation(s)
- Maria J Comin
- Laboratory of Medicinal Chemistry, Center for Cancer Research, National Cancer Institute-Frederick, National Institutes of Health, 376 Boyles Street, Frederick, Maryland 21702, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Carter CA, Hamm JT. Multiplexed quantitative high content screening reveals that cigarette smoke condensate induces changes in cell structure and function through alterations in cell signaling pathways in human bronchial cells. Toxicology 2009; 261:89-102. [PMID: 19394402 DOI: 10.1016/j.tox.2009.04.039] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2009] [Revised: 04/06/2009] [Accepted: 04/15/2009] [Indexed: 12/27/2022]
Abstract
Human bronchial cells are one of the first cell types exposed to environmental toxins. Toxins often activate nuclear factor-kappaB (NF-kappaB) and protein kinase C (PKC). We evaluated the hypothesis that cigarette smoke condensate (CSC), the particulate fraction of cigarette smoke, activates PKC-alpha and NF-kappaB, and concomitantly disrupts the F-actin cytoskeleton, induces apoptosis and alters cell function in BEAS-2B human bronchial epithelial cells. Compared to controls, exposure of BEAS-2B cells to doses of 30mug/ml CSC significantly activated PKC-alpha, while CSC doses above 20mug/ml CSC significantly activated NF-kappaB. As NF-kappaB was activated, cell number decreased. CSC treatment of BEAS-2B cells induced a decrease in cell size and an increase in cell surface extensions including filopodia and lamellipodia. CSC treatment of BEAS-2B cells induced F-actin rearrangement such that stress fibers were no longer prominent at the cell periphery and throughout the cells, but relocalized to perinuclear regions. Concurrently, CSC induced an increase in the focal adhesion protein vinculin at the cell periphery. CSC doses above 30mug/ml induced a significant increase in apoptosis in BEAS-2B cells evidenced by an increase in activated caspase 3, an increase in mitochondrial mass and a decrease in mitochondrial membrane potential. As caspase 3 increased, cell number decreased. CSC doses above 30mug/ml also induced significant concurrent changes in cell function including decreased cell spreading and motility. CSC initiates a signaling cascade in human bronchial epithelial cells involving PKC-alpha, NF-kappaB and caspase 3, and consequently decreases cell spreading and motility. These CSC-induced alterations in cell structure likely prevent cells from performing their normal function thereby contributing to smoke-induced diseases.
Collapse
Affiliation(s)
- Charleata A Carter
- A.W. Spears Research Center, 420 N. English Street, Lorillard Tobacco Company, Greensboro, NC 27405, USA.
| | | |
Collapse
|
50
|
Hirai G, Ogoshi Y, Ohkubo M, Tamura Y, Watanabe T, Shimizu T, Sodeoka M. Asymmetric synthesis of isobenzofuranone derivatives and their unique character as protein kinase Cα (PKCα) activators. Tetrahedron Lett 2009. [DOI: 10.1016/j.tetlet.2009.03.069] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|